← Back to all articles
PharmacologyPubMed Verified

The psychedelic N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator

Fontanilla D, Johannessen M, Hajra AR, Cozzi NV, Jackson MB, Bhagra AR, Su TP

Science (2009)

Preclinical / in vitro
Abstract

Landmark Science paper: DMT is an endogenous sigma-1 receptor regulator. Sigma-1 receptors modulate ion channel activity and neurotransmitter release, with implications for understanding psychedelic and normal brain function.

Citations750
Study TypePreclinical / in vitro
DMTsigma-1 receptorendogenousScience
DOI: 10.1126/science.1166127View on PubMed

Related Articles

Pharmacology

Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics

Chaves C, Dos Santos RG et al.

Frontiers in Psychiatry, 2024
Pharmacology

The endogenous hallucinogen and trace amine N,N-dimethyltryptamine displays potent protective effects against hypoxia via sigma-1 receptor activation in human primary iPSC-derived cortical neurons and microglia-like immune cells

Szabo A, Kovacs A et al.

Frontiers in Neuroscience, 2016
Pharmacology

Dimethyltryptamine and harmine, components of ayahuasca, prevented cocaine-induced apoptosis in SH-SY5Y human neuroblastoma cells

Salles G, de Carvalho Alves I et al.

Archives of Toxicology, 2025
Pharmacology

Development of a physiologically based pharmacokinetic model of N,N-dimethyltryptamine, harmine, and their interactions from ayahuasca in rats and humans

Wittayakarn N, Tan YM et al.

Toxicological Sciences, 2025